Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Sprog
Alle Felter
Titel
Forfatter
Fag
Klassifikationsnummer
ISBN/ISSN
Tag
Find
Udvidet
Inability to Tolerate Standard...
Citér dette
Stav dette
Email dette
Udskriv
Eksportér post
Eksportér til RefWorks
Eksportér til EndNoteWeb
Eksportér til EndNote
Permanent link
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
Show other versions (2)
Bibliografiske detaljer
Main Authors:
Sive, J
,
Buck, G
,
Fielding, A
,
Lazarus, H
,
Litzow, MR
,
Luger, S
,
Marks, D
,
McMillan, A
,
Richards, S
,
Rowe, J
,
Tallman, MS
,
Goldstone, A
Format:
Conference item
Udgivet:
2010
Beholdninger
Beskrivelse
Other Versions (2)
Lignende værker
Medarbejdervisning
Beskrivelse
Summary:
Lignende værker
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
af: Sive, J, et al.
Udgivet: (2010)
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
af: Sive, J, et al.
Udgivet: (2010)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
af: Sive, J, et al.
Udgivet: (2012)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
af: Fielding, A, et al.
Udgivet: (2007)
Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
af: Fielding, A, et al.
Udgivet: (2010)